RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial

Valvular Heart Disease Clinical Trial

Official title:

A Phase 2, Randomized, Open Label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban Compared With Vitamin K Antagonism in Patients With Atrial Fibrillation With Bioprosthetic Mitral Valves - RIVER

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02303795
• Other study ID #: RIVER01
• Status: Completed
• Phase: Phase 2
• Start date: August 2015
• Est. completion date: August 2020

Study information

• Verified date: April 2022
• Source: Hospital do Coracao
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RIvaroxaban for Valvular heart diseasE and atRial fibrillation trial (RIVER trial).

Description:

A Phase 2, Randomized, Open label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban compared with vitamin K antagonism in Patients with Atrial Fibrillation with Bioprosthetic Mitral valves - RIVER. Main analysis for the primary endpoint are based on the Restricted Mean Survival Time (RMST) method.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1005
• Est. completion date: August 2020
• Est. primary completion date: August 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male and female patients aged >18 years at time of inclusion

2. Patients with Persistent or paroxysmal Atrial Fibrillation or flutter with bioprosthetic mitral valves.

• The patient must be able to give informed consent

Exclusion Criteria:

1. Cardiovascular-related conditions as known presence of cardiac thrombus or tumor

• Active endocarditis
• Uncontrolled hypertension

2. Hemorrhage risk-related criteria

• Active internal bleeding
• History of, or condition associated with, increased bleeding risk

3. Concomitant conditions and therapies

• History of previous thromboembolism with high risk of bleeding:
• Severe, disabling stroke (modified Rankin score of 4-5, inclusive) within 3 months
• Acute thromboembolic events or thrombosis (venous/arterial) within the last 14 days prior to randomization
• Acute MI within the last 14 days prior to randomization
• Treatment with: Chronic aspirin therapy > 100 mg daily or dual antiplatelet therapy; Intravenous antiplatelets; Fibrinolytics; Anticipated need for long-term treatment with a nonsteroidal antiinflammatory drug; Systemic treatment with a strong inhibitor of cytochrome P450 3A4, such as ketoconazole or protease inhibitors; Treatment with a strong inducer of cytochrome P450 3A4, such as rifampicin, phenytoin, phenobarbital, or carbamazepine.
• Anemia
• Pregnancy or breastfeeding or women of reproductive age not using effective contraceptive methods
• Calculated creatinine clearance bellow 30 mL/min
• Known significant liver disease or alanine aminotransferase N3× the upper limit of normal
• Previous participation in this study.

Related Conditions & MeSH terms

• Atrial Fibrillation
• Heart Diseases
• Heart Valve Diseases
• Valvular Heart Disease

Intervention

Drug:
• Rivaroxaban
Patients assigned to rivaroxaban will receive oral rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
• Warfarin
Patients will take the warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0. Patients with 65 > years old, should take warfarin (2,5mg/day) and all others patients should take 5mg/day.

Locations

Country	Name	City	State
Brazil	Associação do Sanatório Sírio - Hospital do Coração HCor	São Paulo	SP

Sponsors (1)

Lead Sponsor	Collaborator
Hospital do Coracao

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Major Clinical Events	Combined Endpoint of major clinical events as defined by strokes (CVA), transient ischemic attack (TIA), major bleeding, all-cause death, valve thrombosis and non-CNS systemic embolism, hospitalization due to cardiac failure.	12 months
Secondary	Major bleeding	Clinically overt bleeding associated with: fatal outcome, involving a critical site, or clinically overt bleeding associated with a fall in hemoglobin concentration of =2 g/dL, or leading to transfusion of =2 units of packed red blood cells or whole blood.	12 months
Secondary	Combined endpoint of nonfatal stroke (CVA), transient ischemic attack (TIA), systemic embolism, valve thrombosis, venous thromboembolism and vascular causes death.thrombosis, and vascular death	Stroke: sudden, focal neurologic deficit from a presumed cerebrovascular cause, not reversible within 24 hours and not due to na identifiable cause.; Non-CNS systemic embolism: abrupt vascular insufficiency associated with clinical or radiologic evidence of arterial occlusion.; Valve thrombosis: any thrombus attached to or near an implanted valve that occludes part of the blood flow, interferes with function or warrant treatment.; Mortality: Deaths any cause. Venous thromboembolism: verification by definitive diagnostic evaluation. Deep Vein Thrombosis: abnormal compression ultrasound or intraluminal filling defect on venography or autopsy.; Pulmonary embolism: at least one: 1) intraluminal filling defect on CT scan; 2) intraluminal filling defect on pulmonary angiogram; 3) high- probability on v/p lung scan; 4)inconclusive spiral CT, pulmonary image with demonstration of DVT in the lower extremities; 5) autopsy	12 months